Mark L. Baum
2017
In 2017, Mark L. Baum earned a total compensation of $913K as Chief Executive Officer at Imprimis Pharmaceuticals, a 71% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $35,968 |
|---|---|
| Option Awards | $303,408 |
| Salary | $417,347 |
| Other | $156,271 |
| Total | $912,994 |
Baum received $417.3K in salary, accounting for 46% of the total pay in 2017.
Baum also received $36K in non-equity incentive plan, $303.4K in option awards and $156.3K in other compensation.
Rankings
In 2017, Mark L. Baum's compensation ranked 9,412th out of 14,666 executives tracked by ExecPay. In other words, Baum earned more than 35.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,412 out of 14,666 | 36th |
Division Manufacturing | 3,620 out of 5,768 | 37th |
Major group Chemicals And Allied Products | 1,248 out of 2,074 | 40th |
Industry group Drugs | 1,003 out of 1,730 | 42nd |
Industry Pharmaceutical Preparations | 788 out of 1,329 | 41st |
Source: SEC filing on April 30, 2018.
Baum's colleagues
We found two more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2017.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019